Aclaris Therapeutics Inc Stock Research

Market Summary

USD17.48+0.66

Market Closed

3.92%

ACRS Alerts

1 major insider sales recently.

ACRS Stock Price

ACRS RSI Chart

ACRS Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

-14.2

Price/Sales (Trailing)

49.6

EV/EBITDA

-11.61

Price/Free Cashflow

-17.6

ACRS Price/Sales (Trailing)

ACRS Profitability

Operating Margin

81.72%

EBT Margin

-1479.64%

Return on Equity

-37.34%

Return on Assets

-30.67%

Free Cashflow Yield

-5.68%

ACRS Fundamentals

ACRS Revenue

Revenue (TTM)

23.5M

Revenue Y/Y

1.0K%

Revenue Q/Q

1.1K%

ACRS Earnings

Earnings (TTM)

-82.1M

Earnings Y/Y

5.65%

Earnings Q/Q

2.82%

Price Action

52 Week Range

9.8418.96

(Low)(High)

Last 7 days

5.0%

Last 30 days

12.9%

Last 90 days

13.7%

Trailing 12 Months

73.1%

ACRS Financial Health

Current Ratio

12.97

Debt/Equity

0.05

Debt/Cashflow

-6.37

ACRS Investor Care

Shares Dilution (1Y)

8.92%

Diluted EPS (TTM)

-1.29

Peers (Alternatives to Aclaris Therapeutics)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	442.1B	96.0B	-4.77%	1.21%	23.08	4.6	5.02%	7.14%
LLY	308.1B	29.2B	-6.33%	46.49%	51.07	10.54	5.34%	1.02%
MRK	267.0B	59.0B	-5.13%	34.98%	17.49	4.53	27.84%	112.03%
PFE	245.5B	99.9B	-13.80%	-15.92%	8.25	2.46	45.01%	53.21%
BMY	154.0B	46.7B	0.64%	15.96%	23.07	3.3	2.79%	223.53%
MID-CAP
PRGO	5.0B	4.4B	10.03%	-0.57%	-46.66	1.14	1.80%	57.67%
SUPN	2.2B	659.0M	13.79%	40.18%	57.51	3.29	16.78%	-53.92%
SMALL-CAP
TLRY	1.9B	613.6M	24.42%	-38.51%	-3.79	3.14	37.73%	-7.19%
RETA	1.6B	3.1M	23.90%	79.89%	-5.08	503.44	-77.09%	-12.24%
CGC	1.4B	-	33.79%	-57.23%	-0.46	1.95	-4.11%	-144.36%
ACRS	1.2B	23.5M	12.85%	73.07%	-14.2	49.6	243.57%	-1.04%
CRON	942.1M	112.7M	-	-24.55%	-4.21	8.36	45.53%	40.26%
INVA	885.5M	-	-2.61%	-19.99%	2.65	2.34	10.49%	-16.07%
OCUL	298.8M	49.7M	46.97%	-25.95%	-5.03	6.01	28.95%	32.80%
ENDP	94.1M	2.6B	-43.99%	-88.43%	-0.03	0.04	-13.88%	-4855.92%

Financials for Aclaris Therapeutics

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	282.7%	23,500,000	6,141,000	6,437,000	6,761,000	6,840,000
S&GA Expenses	-0.7%	24,930,000	25,096,000	24,891,000	23,619,000	21,574,000
R&D Expenses	15.8%	70,843,000	61,163,000	50,281,000	43,813,000	38,667,000
EBITDA	0.0%	-90,063,000.00	-90,022,000.00	-	-	-
EBITDA Margin	-4.9%	-14.67	-13.99	-	-	-
Earnings Before Taxes	-	-90,865,000.00	-	-	-	-
EBT Margin	-4.8%	-14.80	-14.12	-	-	-
Net Income	1.4%	-82,077,000.00	-83,271,000.00	-80,900,000.00	-90,865,000.00	-81,234,000.00
Net Income Margin	74.2%	-3.49	-13.56	-12.57	-13.44	-
Free Cahsflow	3.9%	-66,227,000.00	-68,922,000.00	-61,431,000.00	-52,442,000.00	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Assets	-3.7%	268	278	227	251	263
Current Assets	-1.1%	257	259	191	205	206
Cash Equivalents	-9.7%	62	68	36	27	54
Net PPE	-10.3%	1	1	1	1	1
Liabilities	13.2%	48	42	46	54	47
Current Liabilities	22.0%	20	16	17	23	18
Shareholder's Equity	-6.8%	220	236	180	197	217
Retained Earnings	-3.1%	-654.68	-634.73	-614.20	-595.41	-572.60
Additional Paid-In Capital	0.5%	876	872	795	793	789
Shares Outstanding	0.0%	67	67	62	61	61

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Cashflow From Operations	4.1%	-65.53	-68.32	-60.87	-52.13	-43.92
Share Based Compensation	3.6%	14	14	14	14	13
Cashflow From Investing	102.0%	1	-38.14	-62.39	-167.63	-160.76
Cashflow From Financing	18.9%	73	61	124	225	233

Risks for ACRS

What is the probability of a big loss on ACRS?

100%

Probability that Aclaris Therapeutics stock will be more than 20% underwater in next one year

100%

Probability that Aclaris Therapeutics stock will be more than 30% underwater in next one year.

91.2%

Probability that Aclaris Therapeutics stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ACRS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Aclaris Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for ACRS

Cumulative Returns on ACRS

-3.4%

7-Year Cumulative Returns

-6.5%

5-Year Cumulative Returns

130.4%

3-Year Cumulative Returns

What are the long-term rolling returns for ACRS?

FIve years rolling returns for Aclaris Therapeutics.

Annualized Returns

Which funds bought or sold ACRS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-01-26	STRS OHIO	added	82.91	260,000	573,000	-%
2023-01-25	Lindbrook Capital, LLC	reduced	-12.97	-724	3,276	-%
2023-01-23	Allspring Global Investments Holdings, LLC	reduced	-1.25	-11,415	1,028,580	-%
2023-01-18	Verition Fund Management LLC	added	122.61	7,054,000	11,726,000	0.07%
2023-01-12	Assenagon Asset Management S.A.	unchanged	-	2,000	3,070,000	0.01%
2023-01-06	MASSMUTUAL TRUST CO FSB/ADV	unchanged	-	-	1,000	-%
2022-11-22	TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY	new	-	850,000	850,000	0.01%
2022-11-21	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	5.84	168,000	1,033,000	-%
2022-11-17	Telemetry Investments, L.L.C.	sold off	-100	-154,000	-	-%
2022-11-16	BNP PARIBAS ARBITRAGE, SNC	added	57.77	145,241	331,705	-%

Latest Funds Activity

Are funds buying ACRS calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own ACRS

No. of Funds

ACRS Alerts

1 major insider sales recently.

Aclaris Therapeutics News

Schedule 13G FIlings of Aclaris Therapeutics

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 25, 2022	ra capital management, l.p.	7.1%	4,398,453	SC 13G
Feb 15, 2022	rock springs capital management lp	6.31%	3,861,347	SC 13G/A
Feb 14, 2022	venrock healthcare capital partners ii, l.p.	7.5%	4,563,962	SC 13G
Feb 11, 2022	foresite capital fund iii, l.p.	0.0%	0	SC 13G/A
Feb 04, 2022	blackrock inc.	6.7%	4,078,875	SC 13G
Feb 04, 2022	wellington management group llp	9.05%	5,539,268	SC 13G
Jan 24, 2022	biotechnology value fund l p	3.4%	2,093,085	SC 13G
Feb 16, 2021	rock springs capital management lp	6.24%	2,676,100	SC 13G/A
Feb 12, 2021	ecor1 capital, llc	3.5%	1,509,812	SC 13G/A
Feb 11, 2021	adage capital partners gp, l.l.c.	5.24%	2,250,000	SC 13G/A

ACRS Fair Value

Recent SEC filings of Aclaris Therapeutics

View All Filings

Date Filed	Form Type	Document
Jan 20, 2023	4	Insider Trading
Jan 09, 2023	8-K	Current Report
Jan 06, 2023	3	Insider Trading
Jan 06, 2023	8-K	Current Report
Jan 04, 2023	4	Insider Trading
Dec 16, 2022	4	Insider Trading
Dec 13, 2022	8-K	Current Report
Nov 22, 2022	8-K	Current Report
Nov 14, 2022	4	Insider Trading
Nov 08, 2022	10-Q	Quarterly Report

Latest Insider Trading transactions for ACRS

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-01-04	Walker Neal	sold	-223,342	14.8895	-15,000	-
2023-01-03	Walker Neal	sold	-381,213	15.2485	-25,000	-
2022-12-15	Monahan Joseph	sold	-79,411.5	15.8823	-5,000	chief scientific officer
2022-11-14	SCHIFF ANDREW N	sold	-23,416.7	17.08	-1,371	-
2022-11-11	SCHIFF ANDREW N	sold	-702,177	17.0597	-41,160	-
2022-11-10	SCHIFF ANDREW N	sold	-193,995	17.0246	-11,395	-
2022-11-08	Powell Andrew Kenneth William	gifted	-	-	-4,000	-
2022-10-26	SCHIFF ANDREW N	sold	-247,253	17.005	-14,540	-
2022-10-25	SCHIFF ANDREW N	sold	-204,516	17.0175	-12,018	-
2022-10-24	SCHIFF ANDREW N	sold	-248,586	17.0078	-14,616	-

About Aclaris Therapeutics

Neal S. Walker

www.aclaristx.com

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

ACRS Income Statement

2022-09-30

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues:
Total revenue	$ 19,018	$ 1,659	$ 21,999	$ 5,260
Costs and expenses:
Cost of revenue	923	1,099	3,146	3,564
Research and development expense	23,656	13,976	56,741	29,711
General and administrative expense	5,813	5,979	17,987	16,676
Licensing	7,300		7,300
Revaluation of contingent consideration	2,200	900	(2,400)	22,139
Total costs and expenses	39,892	21,954	82,774	72,090
Loss from operations	(20,874)	(20,295)	(60,775)	(66,830)
Other income (expense), net	922	(851)	1,502	(1,231)
Net loss	$ (19,952)	$ (21,146)	$ (59,273)	$ (68,061)
Net loss per share, basic	$ (0.30)	$ (0.35)	$ (0.92)	$ (1.23)
Net loss per share, diluted	$ (0.30)	$ (0.35)	$ (0.92)	$ (1.23)
Weighted average common shares outstanding, basic	66,675,337	61,219,321	64,718,008	55,215,037
Weighted average common shares outstanding, diluted	66,675,337	61,219,321	64,718,008	55,215,037
Other comprehensive (loss) income:
Unrealized gain (loss) on marketable securities, net of tax of $0	$ (139)	$ 5	$ (1,241)	$ (5)
Foreign currency translation adjustment		176		96
Total other comprehensive (loss) income	(139)	181	(1,241)	91
Comprehensive loss	(20,091)	(20,965)	(60,514)	(67,970)
Contract research
Revenues:
Total revenue	1,090	1,415	3,529	4,556
Licensing
Revenues:
Total revenue	17,898	214	18,378	612
Other
Revenues:
Total revenue	$ 30	$ 30	$ 92	$ 92

ACRS Balance Sheet

2022-09-30

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 61,653	$ 27,349
Short-term marketable securities	186,409	164,065
Accounts receivable, net	597	623
Prepaid expenses and other current assets	7,914	12,995
Total current assets	256,573	205,032
Marketable securities		34,242
Property and equipment, net	1,145	1,335
Intangible assets	6,992	7,048
Other assets	2,922	3,554
Total assets	267,632	251,211
Current liabilities:
Accounts payable	7,667	9,985
Accrued expenses	9,154	10,051
Current portion of lease liabilities	766	693
Discontinued operations	2,202	2,202
Total current liabilities	19,789	22,931
Other liabilities	1,638	2,172
Contingent consideration	26,000	28,400
Deferred tax liability	367	367
Total liabilities	47,794	53,870
Commitments and contingencies (Note 16)
Stockholders' Equity:
Preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued or outstanding at September 30, 2022 and December 31, 2021
Common stock, $0.00001 par value; 100,000,000 shares authorized at September 30, 2022 and December 31, 2021; 66,679,641 and 61,228,446 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	1	1
Additional paid-in capital	875,982	792,971
Accumulated other comprehensive loss	(1,465)	(224)
Accumulated deficit	(654,680)	(595,407)
Total stockholders' equity	219,838	197,341
Total liabilities and stockholders' equity	$ 267,632	$ 251,211